Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs Kin Meds

Invyncible
Graded #303

Lower grade

vs+11.900000000000006
Kin Meds
Graded #75

Higher grade

The verdict

Kin Meds takes it — 72.9/100 to 61/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +19
55
74
Dose & formulationKin Meds +29
64
93
Clinical oversightKin Meds +4
70
74
Labs & monitoringKin Meds +1
52
53
FulfillmentKin Meds +7
65
72
Contract termsInvyncible +6
61
55
Invyncible · left barKin Meds · right bar

The numbers

MetricInvyncibleKin Meds
WeighScore61/10072.9/100
GradeCC
Scorecard rank#303#75
Semaglutide$192/mo (0.5 mg dose, compounded)$149/mo (brand Wegovy)
Tirzepatide$210/mo (compounded)$149/mo (brand Zepbound)
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Invyncible

Graded #303 · C

Strengths

  • Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
  • Physical corporate address published (St. Petersburg, FL)
  • LegitScript verification seal displayed
  • No long-term commitment required
  • Offers both semaglutide and tirzepatide programs

Where it loses points

  • Pricing not disclosed on the public site — fully gated behind signup
  • Drug forms (compounded vs brand, injection vs oral) not disclosed
  • 503A vs 503B designation not specified
  • Pharmacy partner not named
  • States served not listed publicly
Kin Meds

Graded #75 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard